- Short report
- Open Access
Temporal regulation of HTLV-2 expression in infected cell lines and patients: evidence for distinct expression kinetics with nuclear accumulation of APH-2 mRNA
- Cecilia Bender†1,
- Francesca Rende†2,
- Alessia Cotena1,
- Paola Righi1,
- Paola Ronzi3,
- Ilaria Cavallari2,
- Claudio Casoli3, 5,
- Vincenzo Ciminale†2, 4Email author and
- Umberto Bertazzoni1Email author
© Bender et al.; licensee BioMed Central Ltd. 2012
- Received: 22 December 2011
- Accepted: 18 August 2012
- Published: 13 September 2012
Human T-cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-2) are delta retroviruses with similar genetic organization. Although both viruses immortalize T-cells in vitro, they exhibit distinct pathogenic potential in vivo. To search for possible differences in its expression strategy with respect to HTLV-1, we investigated the pattern of HTLV-2 expression in infected cell lines and peripheral blood mononuclear cells (PBMCs) from infected patients using splice site-specific quantitative RT-PCR.
A novel alternative splice acceptor site for exon 2 was identified; its usage in env transcripts was found to be subtype-specific. Time-course analysis revealed a two-phase expression kinetics in an infected cell line and in PBMCs of two of the three patients examined; this pattern was reminiscent of HTLV-1. In addition, the minus-strand APH2 transcript was mainly detected in the nucleus, a feature that was similar to its HTLV-1 orthologue HBZ. In contrast to HTLV-1, expression of the mRNA encoding the main regulatory proteins Tax and Rex and that of the mRNAs encoding the p28 and truncated Rex inhibitors is skewed towards p28/truncated Rex inhibitors in HTLV-2.
Our data suggest a general converging pattern of expression of HTLV-2 and HTLV-1 and highlight peculiar differences in the expression of regulatory proteins that might influence the pathobiology of these viruses.
- Proviral Load
- Splice Acceptor Site
- Expression Kinetic
- Viral Expression
- Normalize Copy Number
Human T-cell leukemia virus types 1 and 2 (HTLV-1 and HTLV-2) are related deltaretroviruses  with similar genetic organization and expression strategies [2–4]. Both viruses immortalize T-cells in culture and establish a persistent infection in vivo . However, unlike HTLV-1, which causes adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM), HTLV-2 has not been linked to lymphoproliferative diseases although an increase in lymphocytes counts was described in HTLV-2-infected patients  and coinfection with HTLV-2 plays an important role in the progression of HIV-infected patients to AIDS .
Identification of a novel HTLV-2 splice acceptor-site
Quantitative and temporal analysis of HTLV-2 mRNAs in infected cell lines
Using two splice site-specific primer pairs, we quantified the levels of the alternative env transcripts [env(1–2) and env(1-2iso)] from the Mo-T and BJAB-Gu cell lines and in cells transfected with the HTLV-2A molecular clone pH6neo (kindly provided by Dr. P. L. Green). Results showed that the env(1-2iso) mRNA was expressed at similar levels in both cell lines, while the canonic env(1–2) transcript was about 100-fold less abundant in BJAB-Gu cells (Figure 3A). Interestingly, the HTLV-2A molecular clone pH6neo also expressed mainly env(1–2), suggesting a subtype-specific usage of the 2 vs. 2iso 3’SS (Figure 3A). While the sequence of the acceptor and donor dinucleotides is conserved between the two isolates, the adjacent nucleotides are different (Figure 2C), suggesting that this could result in a different splice site usage in the different isolates. The 1-2iso splice acceptor site was also used in the context of a doubly spliced tax/rex (1-2iso-3) mRNA which was readily detected in both cell lines and in the molecular clone pH6neo (data not shown). Selection of 1-2iso 3'SS as opposed to the 1–2 3'SS is not predicted to affect the coding potential of the env (1–2; 1-2iso), tax/rex (1-2-3; 1-2iso-3) or 1-2-B and 1-2iso-B mRNAs, as both 3'SS are located in the non-coding portion of the transcripts. Interestingly, the 1-2iso splice site is not unique to only the BJAB-Gu cell line, as it is efficiently used in the patients, which are infected with subtype 2B (see next paragraph).
In the chronically infected cell lines Mo-T and BJAB-Gu as well as in cells transfected with the pH6neo molecular clone the most abundant viral mRNA was gag/pol followed by tax/rex(1-2-3), env and p28/trex(1 3) (Figure 3A); the latter codes for p28 and the truncated isoforms of Rex (p22/20 and p19/p18). We proposed to term these truncated isoforms of Rex as “tRex” . Both p28 and tRex may act as latency factors by inhibiting the tax/rex mRNA  and the Rex protein, respectively . Interestingly, in HTLV-2 tax/rex was detected at levels comparable to p28/trex taxrex/trex(1–3) ratio = 0.5 in pH6neo-transfections; 1.04 in Mo-T; 0.69 in BJAB-Gu]. This is in contrast with HTLV-1, where tax/rex is much more abundant than the mRNAs coding for p30Tof and p21Rex, the orthologs of p28 and tRex, respectively . These data suggest that the ratio of expression of the tax/rex mRNA vs. the mRNAs encoding potential inhibitors is higher in HTLV-1 compared to HTLV-2. The p28 and tRex proteins are also coded by the less abundant p28/trex(1-B) mRNA. Transcript 1-2-B, whose protein product has not yet been identified and is also expressed as 1-2iso-B; the p11/p10(1-2-A) transcript and the minus-strand APH-2 transcript were all expressed at lower levels. These data are consistent with a previous study by Li et al. .
A recent study on the intracellular distribution of HTLV-1 mRNAs indicated that the plus-strand transcripts showed similar partition in the nucleus and cytoplasm, while the minus-strand mRNAs were over 10-fold more abundant in the nucleus, suggesting that they may play a role as a non-coding RNAs . To test whether this is the case for HTLV-2, we analyzed the nucleo-cytoplasmic distribution of plus- and minus-strand HTLV-2 mRNAs. Results obtained in the Mo-T and BJAB-Gu infected cell lines showed that all the plus-strand mRNAs were equally distributed in the nucleus and cytoplasm, while the minus-strand APH-2 mRNA  was about 10-fold or 4-fold higher (Mo-T and BJAB-Gu cell lines, respectively) in the nucleus (Figure 3B; Mann–Whitney Rank Sum Test; p = 0.001 and p = 0.002 for the Mo-T and BJAB-Gu cell lines respectively). This finding is reminiscent of cell lines chronically infected with HTLV-1 .
We next investigated whether, in analogy to HTLV-1 , HTLV-2 is characterized by an early/late temporal pattern of expression. To test this possibility in an in vitro model, we induced HTLV-2 expression in BJAB-Gu cells by diluting to 25,000 cells/ml starting from a confluent culture and measured transcript levels over 96 h by qRT-PCR. As indicated in Figure 3C, this treatment results in an overall upregulation of viral expression. To ensure that the pattern of viral expression was not affected by cell death, we tested cell viability by trypan blue exclusion at each time point and found that cell death did not exceed 4% for up to 96 h of culture. The amount of p19 released by the BJAB-Gu cells was below the threshold of detection by ELISA at 0 and 24 h and rose to 62 pg/ml at 48 h, 121 pg/ml at 72 h, and 169 pg/ml at 96 h.
To better visualize the timing of expression of individual mRNAs, we calculated the scaled copy number (SCN) by dividing the normalized copy number (NCN) of each transcript at each time point by the maximum NCN measured for that mRNA during the experiment. Results showed 2-phase kinetics with the expression of tax/rex(1-2-3), p28/tRex(1-B) and 1-2-B preceding that of gag/pol, env and p28/trex(1–3) mRNAs (Figure 3D), a finding that is consistent with the key role of Tax and Rex as master regulatory proteins driving expression of the other viral genes.
Temporal analysis of HTLV-2 expression in PBMCs from infected patients
We next used qRT-PCR to investigate HTLV-2 expression kinetics in PBMCs obtained from 3 HTLV-2B-infected patients; these patients had similar proviral loads and were HTLV-1- and HIV-1-negative (Additional file 2: Table S2). All of the recruited patients gave informed consent, according to the Italian laws and the Declaration of Helsinki. The study was approved by the institutional ethics committees of all participating institutions. As described for HTLV-1 , a sharp upregulation of HTLV-2 transcripts was observed upon culture of the PBMCs in all the examined patients (Figure 4A). Before in vitro culture only gag/pol, APH2 and tax/rex(1-2-3) were detected in all patients; p28/trex(1 3) was detected only in patient A (Figure 4B, grey bars). Upon in vitro culture the expression of all transcripts was sharply upregulated (Figure 4B, black bars); however, patient C exhibited a marked downregulation of APH-2. Following reactivation, gag/pol was the most abundant transcript. Tax/rex(1-2-3), p28/trex(1 3), APH-2, and in patients A and B, 1-2-B were also readily detected, while the other transcripts were expressed at much lower levels. Consistent with the fact that the patients were infected with HTLV-2 subtype B, env(1-2iso) was efficiently detected, while env(1–2) was undetectable. Patient C did not express p28/trex(1-B) or (1-2-B). p11/p10(1-2-A) was below the threshold of detection in all patients. The tax/rex over p28/trex(1–3) ratio ranged between 0.9 and 7.6 (depending on the time point) in patient A, and was even more skewed in favor of p28/trex(1–3) in patient B (ratios between 0.04 and 0.37, depending on the time point).
SCN calculations (Figure 4C) indicated a two-phase kinetics of HTLV-2 gene expression in patients A and B, with an early sharp rise in tax/rex(1-2-3) expression followed by expression of all other genes. Patient B also expressed p28/trex(1-B) as an early transcript, although it its expression levels were lower by about 3 orders of magnitude compared to the p28/tRex(1–3) (Figure 4B).
The expression pattern of patients A and B is similar to that of the BJAB-Gu cell line (Figure 3D) and suggests an early/late switch in the pattern of viral expression. While plus-strand transcripts showed an overall common pattern of expression in two patients and in the BJAB-Gu cell line, the temporal expression of APH-2 appeared to be highly variable, at least in the restricted number of samples examined. Further studies carried out on larger cohorts of samples should be performed, to test the possible correlation of different APH-2 expression patterns with virus load and patient status. In this regard, a recent study showed that both Tax and APH-2 mRNA levels correlate with proviral load; interestingly, no correlation was found between APH-2 levels and the number of lymphocytes in the patients, suggesting that, in contrast to HBZ, APH-2 does not promote cell proliferation .
Although the temporal pattern of HTLV-2 expression was reminiscent of that of HTLV-1, it is noteworthy that the most abundant HTLV-2 mRNA encoding p28 and tRex (i.e. mRNA1-3) was expressed from a “late” transcript, while HTLV-1 p21Rex was expressed as an early transcript in most patients examined in a previous study .
Taken together with previous analyses of HTLV-1 expression, the present study suggests a converging expression strategy of the two viruses characterized by 2-phase expression kinetics of viral mRNAs and by marked nuclear localization of minus-strand transcripts. Our results also highlight the following differences between the 2 viruses: (i) the relative expression of the tax/rex mRNA compared to the mRNAs coding for potential inhibitors of Tax (p30Tof and p28) and Rex [(p21Rex and p28/tRex(1–3)] is skewed toward tax/rex in HTLV-1 and towards the inhibitors in HTLV-2; (ii) the p28/trex mRNA was expressed as a “late” transcript in HTLV-2 while mRNAs for HTLV-1 orthologs p30/Tof and p21Rex are expressed early in most patients examined, suggesting interesting differences in the fine-tuning of Rex function between the two viruses. Nevertheless, it is appropriate to be cautious in the interpretation of these data, since only three patients were examined. This limitation was due to the fact that the kinetics analysis required (i) large numbers of PBMC, (ii) a high proviral load, and (iii) no coinfection with HIV or HTLV-1, which severely limited the number of samples suitable for this analysis.
Future studies should be aimed at further investigating the functions of these regulatory proteins in HTLV-1 and HTLV-2 and at understanding how they may contribute to the different pathobiology of the two viruses.
We thank Donna D'Agostino, Luigi Chieco-Bianchi, Elisabetta Pilotti and Maria Grazia Romanelli for discussions. This work was supported by grants from the European Union (“The role of chronic infections in the development of cancer,” contract no. 2005–018704), the Associazione Italiana per la Ricerca sul Cancro (AIRC), the AIRC 2008-Cariverona Regional grant (UB and VC), the Ministero per l’Università e la Ricerca Scientifica e Tecnologica, and the Universities of Padova and Verona.
- Lairmore M, Franchini G: Fields Virology. Edited by: Knipe D, Howley P. 2007, Philadelpia: Lippincott Williams and Wilkins, 2071-2106. vol. 2, FifthGoogle Scholar
- Ciminale V, Pavlakis GN, Derse D, Cunningham CP, Felber BK: Complex splicing in the human T-cell leukemia virus (HTLV) family of retroviruses: novel mRNAs and proteins produced by HTLV type I. J Virol. 1992, 66: 1737-PubMed CentralPubMedGoogle Scholar
- Koralnik IJ, et al: Protein isoforms encoded by the pX region of human T-cell leukemia/lymphotropic virus type I. Proc Natl Acad Sci U S A. 1992, 89: 8813-10.1073/pnas.89.18.8813.PubMed CentralView ArticlePubMedGoogle Scholar
- Ciminale V, et al: Expression and characterization of proteins produced by mRNAs spliced into the X region of the human T-cell leukemia/lymphotropic virus type II. Virology. 1995, 209: 445-10.1006/viro.1995.1277.View ArticlePubMedGoogle Scholar
- Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007, 7: 270-10.1038/nrc2111.View ArticlePubMedGoogle Scholar
- Bartman MT, et al: Long-term increases in lymphocytes and platelets in human T-lymphotropic virus type II infection. Blood. 2008, 112: 3995-10.1182/blood-2008-05-155960.PubMed CentralView ArticlePubMedGoogle Scholar
- Casoli C, Pilotti E, Bertazzoni U: Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. AIDS Rev. 2007, 9: 140-PubMedGoogle Scholar
- Feuer G, Green PL: Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2. Oncogene. 2005, 24: 5996-10.1038/sj.onc.1208971.PubMed CentralView ArticlePubMedGoogle Scholar
- Younis I, Green PL: The human T-cell leukemia virus Rex protein. Front Biosci. 2005, 10: 431-10.2741/1539.PubMed CentralView ArticlePubMedGoogle Scholar
- Rende F, et al: Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNA. Blood. 2011, 117 (18): 4855-4859. 10.1182/blood-2010-11-316463.View ArticlePubMedGoogle Scholar
- Rende F, et al: Comparison of the genetic organization, expression strategies, and oncogenic potential of HTLV-1 and HTLV-2. Leukemia Research and Treatment. 2012, Volume 2012 (2012), Article ID 876153, 14 pagesGoogle Scholar
- Nicot C, et al: HTLV-1-encoded p30(II) is a post-transcriptional negative regulator of viral replication. Nat Med. 2004, 10 (2): 197-201. 10.1038/nm984.View ArticlePubMedGoogle Scholar
- Ciminale V, Zotti L, D'Agostino DM, Chieco-Bianchi L: Inhibition of human T-cell leukemia virus type 2 Rex function by truncated forms of Rex encoded in alternatively spliced mRNAs. J Virol. 1997, 71: 2810-PubMed CentralPubMedGoogle Scholar
- Li M, Green PL: Detection and quantitation of HTLV-1 and HTLV-2 mRNA species by real-time RT-PCR. J Virol Methods. 2007, 142: 159-10.1016/j.jviromet.2007.01.023.PubMed CentralView ArticlePubMedGoogle Scholar
- Halin M, et al: Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription. Blood. 2009, 114: 2427-10.1182/blood-2008-09-179879.PubMed CentralView ArticlePubMedGoogle Scholar
- Douceron E, et al: HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis. J Infect Dis. 2012, 205: 82-10.1093/infdis/jir708.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.